Clinical implementation of ultra-fast molecular testing improves time to result and laboratory throughput.
Goes, Netherlands, March 31, 2021 — Dutch biotechnology company, Molecular Biology Systems, B.V. (MBS) has announced that Aruba’s Laboratorio di Servicio (LdS) has validated and implemented NextGenPCR for SARS-CoV-2 testing. With a single NextGenPCR system capable of producing over 1,000 results per day, Laboratorio di Servicio has ensured they have capacity beyond their current 300 test results per day.
“Last January, our lab Laboratorio di Servicio implemented the MBS’ NextGenPCR solution for CoV2 screening, on Aruba.” says Director of Clinical Chemistry at LdS, Robert Wever. “We found this ultra-fast PCR technology easy to use, sensitive, specific and overall, really ultra-fast, both in throughput as well as time to result.”
MBS has advanced the readout methodology first described last year in collaboration with the University of Bielefeld, to also be compatible with multi-color PCR assays that can monitor additional viral targets and process controls present in clinical diagnostic assays. Labs using ultra-fast RT-PCR in combination with proven SARS-CoV-2 tests and direct from sample RT-PCR has resulted in more than doubling their testing capacity.
“Throughout, labs have wanted to deliver more by increasing the efficiency of their workflow. So, Laboratorio di Servicio is just one example of how NextGenPCR has delivered higher throughput by reducing time spent on RT-PCR.”
About Molecular Biology Systems
Molecular Biology Systems, B.V., founded in 2015, is a life sciences solutions company based in Netherlands. Their NEXTGENPCR thermocycler uses patented heating and cooling technology to reduce PCR amplification cycles from hours to minutes. These technological advances are intended to support laboratorians across the life sciences market reduce costs and accelerate results.
About Laboratorio di Servicio N.V.
Laboratorio di Servicio N.V (LdS), formerly Service Lab Xpert, started delivering laboratory services to Aruba in August 2012. The focus of LdS is primary care, services to medical specialists, institutions, veterinary practices and private companies. LdS offers different clinical tests for allergy, diabetes, anemia, cancer, drug abuse, thyroid, pregnancy, the digestive system and more.
All referenced product names, and other marks, are trademarks of their respective owners.
© 2021 Molecular Biology Systems, B.V. All rights reserved.
Media contact:
Brian McNally, PhD
Molecular Biology Systems B.V.
Brian.mcnally@mbspcr.com
+1 301.366.1083
